Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CRON Stock Forecast 2026-2027
$2.53
Current Price
$973.09M
Market Cap
Buy 3
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to CRON Price Targets
-10.5%
To High Target of $2.26
-10.5%
To Median Target of $2.26
-10.5%
To Low Target of $2.26
CRON Price Momentum
0.0%
1 Week Change
+0.4%
1 Month Change
+47.1%
1 Year Change
-3.8%
Year-to-Date Change
-26.2%
From 52W High of $3.43
+58.1%
From 52W Low of $1.60
📊 TOP ANALYST CALLS
Did CRON Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Cronos Group is one of their latest high-conviction picks.
Latest CRON Stock Price Targets & Analyst Predictions
Based on our analysis of 8 Wall Street analysts, CRON has a bullish consensus with a median price target of $2.26 (ranging from $2.26 to $2.26). The overall analyst rating is Strong Buy (9.0/10). Currently trading at $2.53, the median forecast implies a -10.5% downside. This outlook is supported by 3 Buy, 1 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CRON Analyst Ratings
3
Buy
1
Hold
0
Sell
CRON Price Target Range
Low
$2.26
Average
$2.26
High
$2.26
Current: $2.53
Latest CRON Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CRON.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 15, 2024 | CIBC | John Zamparo | Outperformer | Maintains | $3.50 |
| Apr 8, 2024 | B of A Securities | Lisa Lewandowski | Underperform | Maintains | $2.50 |
| Dec 28, 2023 | B of A Securities | Lisa Lewandowski | Underperform | Maintains | $2.00 |
| May 15, 2023 | Barclays | Gaurav Jain | Equal-Weight | Maintains | $3.00 |
| Nov 2, 2022 | Bernstein | Nadine Sarwat | Market Perform | Initiates | $3.00 |
| Sep 30, 2022 | Barclays | Gaurav Jain | Equal-Weight | Maintains | $3.50 |
| Mar 22, 2022 | Barclays | Gaurav Jain | Equal-Weight | Upgrade | $N/A |
| Mar 7, 2022 | Piper Sandler | Michael Lavery | Neutral | Maintains | $3.00 |
| Feb 22, 2022 | Canaccord Genuity | Matt Bottomley | Sell | Maintains | $4.25 |
| Feb 22, 2022 | Piper Sandler | Michael Lavery | Neutral | Maintains | $4.00 |
| Jan 27, 2022 | Jefferies | Owen Bennett | Hold | Upgrade | $3.24 |
| Nov 18, 2021 | Barclays | Underweight | Initiates | $N/A | |
| Apr 14, 2020 | Piper Sandler | Neutral | Downgrade | $N/A | |
| Mar 31, 2020 | Canaccord Genuity | Sell | Downgrade | $N/A | |
| Nov 13, 2019 | Bank of America | Buy | Maintains | $N/A | |
| Nov 13, 2019 | B of A Securities | Buy | Maintains | $15.00 | |
| Oct 22, 2019 | Piper Jaffray | Overweight | Maintains | $N/A | |
| Oct 22, 2019 | Piper Sandler | Overweight | Maintains | $12.00 | |
| Aug 13, 2019 | Piper Sandler | Overweight | Initiates | $N/A | |
| Aug 13, 2019 | Piper Jaffray | Overweight | Initiates | $N/A |
Cronos Group Inc. (CRON) Competitors
The following stocks are similar to Cronos Group based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Cronos Group Inc. (CRON) Financial Data
Cronos Group Inc. has a market capitalization of $973.09M with a P/E ratio of 24.3x. The company generates $146.59M in trailing twelve-month revenue with a -6.4% profit margin.
Revenue growth is +47.0% quarter-over-quarter, while maintaining an operating margin of -10.1% and return on equity of -0.3%.
Valuation Metrics
Market Cap
$973.09M
Enterprise Value
$196.73M
P/E Ratio
24.3x
PEG Ratio
-63.1x
Price/Sales
6.6x
Growth & Margins
Revenue Growth (YoY)
+47.0%
Gross Margin
+36.4%
Operating Margin
-10.1%
Net Margin
-6.4%
EPS Growth
+47.0%
Financial Health
Cash/Price Ratio
+86.7%
Current Ratio
19.6x
Debt/Equity
0.1x
ROE
-0.3%
ROA
-0.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Cronos Group Inc. (CRON) Business Model
About Cronos Group Inc.
What They Do
Global cannabinoid company focusing on cannabis products.
Business Model
The company generates revenue through the sale of a diverse portfolio of premium cannabis products, including flower, pre-rolls, vapes, gummies, and extracts, targeting both medical and adult-use markets. It also emphasizes small-batch production and innovative formulations to cater to consumer demand, and leverages strategic partnerships to expand its market reach internationally.
Additional Information
Founded in 2018 and headquartered in Toronto, Canada, the company operates primarily in Canada, Israel, and Europe. Notable brands include Spinach®, Lord Jones®, and PEACE NATURALS®, which cater to a variety of consumer preferences. Cronos Group Inc. is actively involved in advancing research and technology within the cannabis sector.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
610
CEO
Mr. Michael Ryan Gorenstein J.D.
Country
Canada
IPO Year
2018
Website
thecronosgroup.comCronos Group Inc. (CRON) Latest News & Analysis
Latest News
Quick Summary
The cannabis industry has gained acceptance, impacting investor sentiment. By 2026, concerns over federal reform have decreased, influencing marijuana stock market reactions positively.
Why It Matters
The cannabis industry's growing acceptance and reduced regulatory fears signal a more stable investment environment, likely enhancing confidence in marijuana stocks and attracting more investors.
Source: MarijuanaStocks
Market Sentiment:
Neutral
Quick Summary
Cronos Group Inc. (CRON:CA) recently presented at the 38th Annual Roth Conference, providing updates that may interest investors in the cannabis sector.
Why It Matters
Cronos Group's presentation at a major conference signals potential insights into its strategic direction and market positioning, influencing investor sentiment and stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Cronos Group (CRON) shares have increased by 46% over the past year, outperforming the cannabis industry significantly.
Why It Matters
Cronos Group's 46% share recovery highlights its strong market performance, suggesting potential growth and confidence in the cannabis sector, which could attract investor interest.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
The global cannabis industry is evolving with expanding legalization. Investors are targeting companies poised for long-term growth, particularly Canadian producers.
Why It Matters
The expansion of cannabis legalization and focus on growth-oriented companies signal potential investment opportunities, particularly in Canadian producers, which can influence market dynamics and valuations.
Source: MarijuanaStocks
Market Sentiment:
Positive
Quick Summary
Cronos Group Inc. reported its Q4 2025 earnings, providing insights on financial performance and future outlook. Further details can be found in the earnings call transcript.
Why It Matters
Cronos Group's Q4 2025 earnings call provides insights into financial performance, growth trends, and market positioning, influencing investor sentiment and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Q4 2025 net revenue rose 47% YoY to $44.5M; FY 2025 net revenue increased 25% YoY to $146.6M.
Why It Matters
Strong revenue growth signals business expansion and demand, potentially boosting investor confidence and stock value. Positive year-over-year trends can attract more investment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About CRON Stock
What is Cronos Group Inc.'s (CRON) stock forecast for 2026?
Based on our analysis of 8 Wall Street analysts, Cronos Group Inc. (CRON) has a median price target of $2.26. The highest price target is $2.26 and the lowest is $2.26.
Is CRON stock a good investment in 2026?
According to current analyst ratings, CRON has 3 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.53. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CRON stock?
Wall Street analysts predict CRON stock could reach $2.26 in the next 12 months. This represents a -10.5% decrease from the current price of $2.53. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Cronos Group Inc.'s business model?
The company generates revenue through the sale of a diverse portfolio of premium cannabis products, including flower, pre-rolls, vapes, gummies, and extracts, targeting both medical and adult-use markets. It also emphasizes small-batch production and innovative formulations to cater to consumer demand, and leverages strategic partnerships to expand its market reach internationally.
What is the highest forecasted price for CRON Cronos Group Inc.?
The highest price target for CRON is $2.26 from at , which represents a -10.5% decrease from the current price of $2.53.
What is the lowest forecasted price for CRON Cronos Group Inc.?
The lowest price target for CRON is $2.26 from at , which represents a -10.5% decrease from the current price of $2.53.
What is the overall CRON consensus from analysts for Cronos Group Inc.?
The overall analyst consensus for CRON is bullish. Out of 8 Wall Street analysts, 3 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $2.26.
How accurate are CRON stock price projections?
Stock price projections, including those for Cronos Group Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 9, 2026 4:04 PM UTC